MedTrace Logo

52-104 Week Off-therapy Second Extension to Study CSPP100A2365

NCT01420068 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 106

Last updated 2019-03-19

Study results available
· View outcomes & findings →

Summary

52-104 week off-therapy second extension to study CSPP100A2365 to assess growth and development in pediatric hypertensive patients previously treated with aliskiren in studies SPP100A2365 and SPP100A2365E1

Conditions

Interventions

DRUG

SPP100

Sponsors & Collaborators

  • Noden Pharma

    lead INDUSTRY

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-19
Primary Completion
2017-08-03
Completion
2017-08-03

Countries

  • United States
  • Guatemala
  • Hungary
  • Poland
  • Puerto Rico
  • Slovakia
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01420068 on ClinicalTrials.gov